文献速递免疫规划

MenACWY-CRM结合疫苗在初种后4-6年加强接种的IIIb期研究

MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
PubMed 文献 · Vaccine · 2019-09-05

这项IIIb期多中心开放标签研究在15-55岁健康人群中评估MenACWY-CRM加强剂免疫应答,受试者此前4-6年接种过MenACWY-CRM或MenACWY-D或未接种。结果显示加强后28天各血清群血清应答率下限均>75%,初种者应答率≥93.24%,未见安全性问题。

要点

  • MenACWY-CRM加强剂在初种后4-6年可诱导强效快速回忆应答。
  • 无论先前接种MenACWY-CRM还是MenACWY-D,加强后应答均充分。
  • 6个月随访期内未发现安全性问题。

核心结论

  • MenACWY-CRM加强剂在青少年和成人中诱导强效快速回忆应答,不受先前接种MenACWY-CRM或MenACWY-D影响,临床安全性可接受。

研究设计与样本

  • IIIb期多中心开放标签研究,15-55岁健康受试者此前4-6年接种MenACWY-CRM(N=301)或MenACWY-D(N=300)或未接种(N=100),均接种一剂MenACWY-CRM。
  • 免疫原性通过人补体血清杀菌试验(hSBA)在接种前、接种后3或5天及28天评估。
  • 安全性监测包括接种后7天反应原性、29天非 solicited 不良事件及181天严重不良事件和就医不良事件。

主要发现

  • 加强后28天,初种者各血清群hSBA血清应答率单侧97.5%CI下限均>75%。
  • 初种者血清应答率≥93.24%,未接种者≥35.87%。
  • 加强后5天,初种者中MenA的hSBA滴度≥1:8比例≥47.14%,MenC、MenW、MenY≥85.52%。
  • 各疫苗血清群hSBA几何平均滴度较基线增加3.25-8.59倍。
  • 6个月随访期内未发现安全性问题。

临床怎么用

  • 支持在初种MenACWY-CRM或MenACWY-D后4-6年使用MenACWY-CRM加强剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination strategies against bacterial meningitis vary across countries. In the United States, a single dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended at 11-12 years of age, with a booster dose approximately 5 years later. We assessed immune responses to a booster dose of MenACWY-CRM vaccine after priming with MenACWY-CRM or MenACWY-D vaccines in adolescents and adults. METHODS: In this phase IIIb, multicenter, open-label study, healthy 15-55-year-olds, who received MenACWY-CRM (N = 301) or MenACWY-D (N = 300) 4-6 years earlier or were meningococcal vaccine-naïve (N = 100), received one MenACWY-CRM vaccine dose. Immunogenicity was evaluated pre-vaccination, 3 or 5 days post-vaccination (sampling subgroups), and 28 days post-vaccination by serum bactericidal activity assay using human complement (hSBA). After vaccination, participants were monitored for 7 days for reactogenicity, 29 days for unsolicited adverse events (AEs), and 181 days for serious AEs and medically-attended AEs. RESULTS: Sufficiency of the immune response to a MenACWY-CRM booster dose was demonstrated; the lower limit of the 1-sided 97.5% confidence interval for percentages of participants with hSBA seroresponse at 28 days post-vaccination was >75% for each serogroup in those primed with either the MenACWY-CRM or MenACWY-D vaccine. Seroresponse was observed in ≥93.24% of primed participants and ≥35.87% of naïve participants 28 days post-vaccination. At 5 days post-booster, among primed participants, hSBA titers ≥1:8 were achieved in ≥47.14% of participants for MenA and in ≥85.52% of participants for MenC, MenW and MenY, and 3.25- to 8.59-fold increases in hSBA geometric mean titers against each vaccine serogroup were observed. No safety concerns were raised throughout the 6-month follow-up period. CONCLUSIONS: A booster dose of the MenACWY-CRM vaccine induced a robust and rapid anamnestic response in adolescents and adults, irrespectively of either MenACWY-CRM or MenACWY-D vaccine administered 4-6 years earlier, with an acceptable clinical safety profile. ClinicalTrials.gov registration: NCT02986854.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tipton M, Daly W, Senders S, et al. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults. Vaccine. 2019. PMID: 31495595. doi:10.1016/j.vaccine.2019.08.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。